ArticleFrontiers in pharmacology2021
Methyl Gallate Improves Hyperuricemia Nephropathy Mice Through Inhibiting NLRP3 Pathway.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Intestinal Multi-Target Mechanisms of Natural Active Substances in Hyperuricemia Alleviation: Recent Progress.Nutrients · 2026Review
- Immunomodulatory Mechanism of Baiyaojian Decoction on Periodontitis: Network Pharmacology, Single-Cell RNA Sequencing and Molecular Docking.Journal of cellular and molecular medicine · 2026Article
- Regulatory mechanisms of programmed cell death in hyperuricaemia and their disease relevance.Frontiers in cell and developmental biology · 2026Review
- Bioactivity and biomedical applications of pomegranate peel extract: a comprehensive review.Frontiers in pharmacology · 2025Review
- Taurine alleviates hyperuricemia-induced nephropathy in rats: insights from microbiome and metabolomics.Frontiers in nutrition · 2025Article
- Shanling Jiangzhi Tea treats hyperuricemia by inhibition of COMT/MAOA signaling pathway and p53/SERPINE1/NLRP3 signaling pathway.Frontiers in endocrinology · 2025Article
- Therapy Targeted to the NLRP3 Inflammasome in Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2024Review
- The role of inflammasomes in human diseases and their potential as therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Phenolic acids from medicinal and edible homologous plants: a potential anti-inflammatory agent for inflammatory diseases.Frontiers in immunology · 2024Review
- A Review on Extracts, Chemical Composition and Product Development of WalnutFoods (Basel, Switzerland) · 2023Review
- Metabolism of Paeoniae Radix Rubra and its 14 constituents in mice.Frontiers in pharmacology · 2022Article
- Integrated transcriptome and metabolome analyses reveal the adaptation of Antarctic mossFrontiers in plant science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia nephropathy (HN) is a form of chronic tubulointerstitial inflammation, caused by the deposition of monosodium urate crystals (MSU) in the distal collecting duct and medullary interstitium, associated with a secondary inflammatory reaction. Numerous published reports indicated that NLRP3 inflammasome pathway play crucial roles in HN symptoms. The present study aims to investigate the protective effects of methyl gallate on HN mice and the underlying mechanisms. An HN model was established by intraperitoneal injection of potassium oxide (PO) to assess the effect of methyl gallate on renal histopathological changes, renal function, cytokine levels and expressions of NLRP3-related protein in HN mice. Moreover,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.